Company Overview
Tenax Therapeutics, Inc. operates as a development-stage pharmaceutical company focused on creating novel cardiopulmonary therapies within the United States. The firm specifically develops TNX-101, TNX-102, and TNX-103 (levosimendan), which have completed phase II clinical trials intended for the treatment of patients with pulmonary hypertension. This entity functions within the Healthcare sector and the Biotechnology industry, positioning it among firms that rely on extensive research and development rather than mature commercial sales streams. With a market capitalization of $240.77M and an employee count of 14, the company maintains a small-scale operational footprint typical of early-to-mid-stage biotechnology ventures. The market cap figure of $240.77M indicates that the market values the company's potential future revenue from its pipeline assets significantly higher than its current lack of commercial sales, reflecting the high-risk, high-reward nature of the biotechnology industry where valuation is often driven by clinical trial progress rather than immediate profitability.
Financial Health
The company reports revenue of N/A for the trailing twelve months, resulting in a net income of $-52,599,000 and an EBITDA of N/A. The absence of reported revenue paired with a substantial net loss reveals a cost structure dominated by research, development, and clinical trial expenses typical for development-stage pharmaceutical companies. Free cash flow stands at $-18,441,624, indicating that the company is currently burning cash to fund its operations and clinical programs rather than generating liquidity from daily business activities. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, a status that confirms the company has not yet achieved commercial revenue necessary to calculate meaningful profitability percentages. On the liability side, the company holds cash of $97.56M while having no debt listed, meaning the debt-to-equity ratio is N/A and the balance sheet is not leveraged with traditional debt obligations. The current ratio is an exceptionally high 14.56, suggesting the company possesses a massive cushion of liquid assets relative to its current liabilities and is not facing immediate short-term liquidity pressures. Return on Equity is -55.6% and return on assets is -35.1%, figures that reveal management is currently utilizing shareholder capital and company assets to generate losses rather than positive returns, a common characteristic for biotechnology firms prior to product approval.
Valuation Assessment
The trailing P/E ratio is N/A due to the lack of net income, while the forward P/E is -9.58, a metric that implies the market expects earnings to remain negative or for the company to remain in a pre-profitability phase for the foreseeable future. The price-to-book ratio is 6.12, indicating that the market values the company at a significant premium of over six times its tangible book value, likely driven by the potential value of its intellectual property and clinical pipeline assets. The price-to-sales ratio is N/A and the EV/EBITDA is also N/A, as these traditional valuation multiples are not applicable to a company with no revenue and negative earnings, forcing reliance on market cap and cash holdings as primary value indicators. The stock has traded between a 52-week low of $4.63 and a 52-week high of $18.38, with the current price position dependent on real-time market fluctuations but historically showing a wide trading range. The beta value of 1.44 indicates that the stock's price volatility is significantly higher than the broader market, moving approximately 44% more aggressively than the market index during periods of rising or falling equity prices.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, reflecting the company's status as a development-stage entity that has not yet transitioned to a revenue-generating phase. Because the company has no reported revenue or earnings, the comparison between earnings growth and revenue growth is not applicable, and the profile is strictly defined by the advancement of its clinical trials rather than financial expansion. The company does not pay a dividend, with a dividend yield of N/A and a payout ratio of 0.0%, which means the firm reinvests all available resources back into its research and development activities rather than distributing income to shareholders. Consequently, the overall growth and income profile is characterized by a complete focus on capital allocation toward clinical development, with no current income generation or shareholder distributions to support investor cash flow needs.